MedPage Today on MSN
New Pill Approved for Schizophrenia, Bipolar Disorder
Milsaperidone is an active metabolite of iloperidone ...
Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be ...
“Lizzie McGuire” and “Revenge of the Nerds” star Robert Carradine has died at the age of 71, with his family confirming that ...
According to Mental Health America, bipolar disorder affects an estimated 4.4% of the United States population. Black ...
Bipolar disorder in young women includes common symptoms, causes, risk factors, and treatment options. Here are key insights to recognise early warning signs and support better mental health.
Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.
Research has shown that Black patients are less likely to be diagnosed with bipolar disorder as opposed to schizophrenia, and ...
The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of ...
FDA approves evidence-based tool (Bysanti) to address severe mood and psychotic symptoms, which may predict future indications.
The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.
A local drugmaker has landed another regulatory approval, this time for a schizophrenia and bipolar treatment — two months ...
The biopharmaceutical company said late Friday that the treatment, called Bysanti, was approved in adults for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results